{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T21:05:34Z","timestamp":1782507934825,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005760","name":"University of Gothenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Intravenous dosing of L- and D-eflornithine in a racemic mixture is a currently recommended late-stage\n                    <jats:italic>gambiense<\/jats:italic>\n                    human African trypanosomiasis (g-HAT) treatment, either as 14-day monotherapy or in combination with oral nifurtimox for seven days. However, an oral eflornithine treatment against late-stage g-HAT would be preferable. Pharmacokinetics of eflornithine are enantioselective with different oral absorption of the enantiomers. L-eflornithine has a greater\n                    <jats:italic>in vitro<\/jats:italic>\n                    antitrypanosomal potency than D-eflornithine. This study aimed to integrate knowledge about\n                    <jats:italic>in vitro<\/jats:italic>\n                    potency and literature data from the only clinical study with enantiospecific pharmacokinetic oral data to predict L-eflornithine concentrations in plasma and cerebrospinal fluid to estimate the probability of target attainment. L- and D-eflornithine concentrations in cerebrospinal fluid from the clinical study with enantiospecific data were described with a compartment model that was validated using external data with total eflornithine concentrations. Simulations were performed with oral L-eflornithine doses ranging between 125 to 1000\u00a0mg\/kg\/day administered twice to twelve times daily. The probability of target attainment analysis showed that oral L-eflornithine doses of 750\u00a0mg\/kg\/day administered four or twelve times daily (i.e., drinking a solution every 2nd hour) as monotherapy would be needed to acquire efficacious exposures. In combination with nifurtimox, L-eflornithine dosed at 375\u00a0mg\/kg\/day four or twelve times daily would give exposures over the threshold concentration in cerebrospinal fluid. The presented simulation framework may serve as a starting point to find a suitable oral dose regimen to assess the clinical potential for an oral L-eflornithine-based combination treatments against late-stage g-HAT.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1208\/s12248-025-01123-9","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T20:15:35Z","timestamp":1757016935000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacokinetics of Racemic Eflornithine in Human Plasma and Cerebrospinal Fluid: Clinical Perspectives for L-eflornithine Against Human African Trypanosomiasis"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4422-6226","authenticated-orcid":false,"given":"Mikael","family":"Boberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kesara","family":"Na-Bangchang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9122-8294","authenticated-orcid":false,"given":"Michael","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1773-197X","authenticated-orcid":false,"given":"Rasmus","family":"Jansson-L\u00f6fmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"issue":"4","key":"1123_CR1","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1172\/JCI21052","volume":"113","author":"PG Kennedy","year":"2004","unstructured":"Kennedy PG. Human African trypanosomiasis of the CNS: current issues and challenges. J Clin Invest. 2004;113(4):496\u2013504. https:\/\/doi.org\/10.1172\/JCI21052.","journal-title":"J Clin Invest"},{"issue":"5","key":"1123_CR2","doi-asserted-by":"publisher","first-page":"e0008261","DOI":"10.1371\/journal.pntd.0008261","volume":"14","author":"JR Franco","year":"2020","unstructured":"Franco JR, Cecchi G, Priotto G, Paone M, Diarra A, Grout L, et al. Monitoring the elimination of human African trypanosomiasis at continental and country level: Update to 2018. PLoS Negl Trop Dis. 2020;14(5):e0008261. https:\/\/doi.org\/10.1371\/journal.pntd.0008261.","journal-title":"PLoS Negl Trop Dis"},{"key":"1123_CR3","unstructured":"World Health Organization. WHO interim guidelines for the treatment of gambiense human African trypanosomiasis. 2019. Available at: www.who.int\/publications\/i\/item\/9789241550567"},{"issue":"3","key":"1123_CR4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1208\/s12248-022-00693-2","volume":"24","author":"C Amilon","year":"2022","unstructured":"Amilon C, Boberg M, Tarning J, Abelo A, Ashton M, Jansson-Lofmark R. Population Pharmacodynamic Modeling of Eflornithine-Based Treatments Against Late-Stage Gambiense Human African Trypanosomiasis and Efficacy Predictions of L-eflornithine-Based Therapy. AAPS J. 2022;24(3):48. https:\/\/doi.org\/10.1208\/s12248-022-00693-2.","journal-title":"AAPS J"},{"issue":"9683","key":"1123_CR5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(09)61117-X","volume":"374","author":"G Priotto","year":"2009","unstructured":"Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, Arnold U, et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet. 2009;374(9683):56\u201364. https:\/\/doi.org\/10.1016\/S0140-6736(09)61117-X.","journal-title":"Lancet"},{"issue":"5","key":"1123_CR6","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/0035-9203(85)90195-6","volume":"79","author":"S Van Nieuwenhove","year":"1985","unstructured":"Van Nieuwenhove S, Schechter PJ, Declercq J, Bone G, Burke J, Sjoerdsma A. Treatment of gambiense sleeping sickness in the Sudan with oral DFMO (DL-alpha-difluoromethylornithine), an inhibitor of ornithine decarboxylase; first field trial. Trans R Soc Trop Med Hyg. 1985;79(5):692\u20138.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"8","key":"1123_CR7","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1371\/journal.pctr.0010039","volume":"1","author":"G Priotto","year":"2006","unstructured":"Priotto G, Fogg C, Balasegaram M, Erphas O, Louga A, Checchi F, et al. Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda. PLoS Clin Trials. 2006;1(8):e39. https:\/\/doi.org\/10.1371\/journal.pctr.0010039.","journal-title":"PLoS Clin Trials"},{"issue":"7","key":"1123_CR8","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1212\/01.wnl.0000208221.55385.55","volume":"66","author":"PG Kennedy","year":"2006","unstructured":"Kennedy PG. Human African trypanosomiasis: in and out of Africa. Neurology. 2006;66(7):962\u20133. https:\/\/doi.org\/10.1212\/01.wnl.0000208221.55385.55.","journal-title":"Neurology"},{"issue":"10","key":"1123_CR9","first-page":"3850","volume":"6","author":"PP Carbone","year":"2000","unstructured":"Carbone PP, Douglas JA, Thomas J, Tutsch K, Pomplun M, Hamielec M, et al. Bioavailability study of oral liquid and tablet forms of alpha-difluoromethylornithine. Clin Cancer Res. 2000;6(10):3850\u20134.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1123_CR10","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1128\/AAC.04101-14","volume":"59","author":"R Jansson-Lofmark","year":"2015","unstructured":"Jansson-Lofmark R, Na-Bangchang K, Bjorkman S, Doua F, Ashton M. Enantiospecific reassessment of the pharmacokinetics and pharmacodynamics of oral eflornithine against late-stage Trypanosoma brucei gambiense sleeping sickness. Antimicrob Agents Chemother. 2015;59(2):1299\u2013307. https:\/\/doi.org\/10.1128\/AAC.04101-14.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3 Spec No","key":"1123_CR11","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/0002-9343(87)90107-0","volume":"82","author":"H Taelman","year":"1987","unstructured":"Taelman H, Schechter PJ, Marcelis L, Sonnet J, Kazyumba G, Dasnoy J, et al. Difluoromethylornithine, an effective new treatment of Gambian trypanosomiasis. Results in five patients. Am J Med. 1987;82(3 Spec No):607\u201314.","journal-title":"Am J Med"},{"issue":"3","key":"1123_CR12","doi-asserted-by":"publisher","first-page":"525","DOI":"10.4269\/ajtmh.1987.37.525","volume":"37","author":"F Doua","year":"1987","unstructured":"Doua F, Boa FY, Schechter PJ, Miezan TW, Diai D, Sanon SR, et al. Treatment of human late stage gambiense trypanosomiasis with alpha-difluoromethylornithine (eflornithine): efficacy and tolerance in 14 cases in Cote d\u2019Ivoire. Am J Trop Med Hyg. 1987;37(3):525\u201333.","journal-title":"Am J Trop Med Hyg"},{"issue":"8820","key":"1123_CR13","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/0140-6736(92)92180-N","volume":"340","author":"F Milord","year":"1992","unstructured":"Milord F, Pepin J, Loko L, Ethier L, Mpia B. Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness. Lancet. 1992;340(8820):652\u20135.","journal-title":"Lancet"},{"issue":"3 Pt 2","key":"1123_CR14","first-page":"578","volume":"81","author":"H Taelman","year":"1988","unstructured":"Taelman H, Marcelis L, Sonnet J, Kazyumba G, Van den Enden E, Wery M, et al. Traitement de la trypanosomiase humaine a Trypanosoma brucei gambiense par l\u2019alpha-difluoromethylornithine. Resultats chez 7 patients. (English: Treatment of human trypanosomiasis caused by Trypanosoma brucei gambiense using alpha-difluoromethylornithine. Results in 7 patients). Bull Soc Pathol Exot Filiales. 1988;81(3 Pt 2):578\u201388.","journal-title":"Bull Soc Pathol Exot Filiales"},{"issue":"3","key":"1123_CR15","first-page":"243","volume":"2","author":"PJ Creaven","year":"1993","unstructured":"Creaven PJ, Pendyala L, Petrelli NJ. Evaluation of alpha-difluoromethylornithine as a potential chemopreventive agent: tolerance to daily oral administration in humans. Cancer Epidemiol Biomarkers Prev. 1993;2(3):243\u20137.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"1123_CR16","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1200\/JCO.1984.2.2.124","volume":"2","author":"MD Abeloff","year":"1984","unstructured":"Abeloff MD, Slavik M, Luk GD, Griffin CA, Hermann J, Blanc O, et al. Phase I trial and pharmacokinetic studies of alpha-difluoromethylornithine\u2013an inhibitor of polyamine biosynthesis. J Clin Oncol. 1984;2(2):124\u201330. https:\/\/doi.org\/10.1200\/JCO.1984.2.2.124.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1123_CR17","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00228-004-0759-7","volume":"60","author":"K Na-Bangchang","year":"2004","unstructured":"Na-Bangchang K, Doua F, Konsil J, Hanpitakpong W, Kamanikom B, Kuzoe F. The pharmacokinetics of eflornithine (alpha-difluoromethylornithine) in patients with late-stage T.b. gambiense sleeping sickness. Eur J Clin Pharmacol. 2004;60(4):269\u201378. https:\/\/doi.org\/10.1007\/s00228-004-0759-7.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1123_CR18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10928-012-9293-x","volume":"40","author":"CC Johansson","year":"2013","unstructured":"Johansson CC, Gennemark P, Artursson P, Abelo A, Ashton M, Jansson-Lofmark R. Population pharmacokinetic modeling and deconvolution of enantioselective absorption of eflornithine in the rat. J Pharmacokinet Pharmacodyn. 2013;40(1):117\u201328. https:\/\/doi.org\/10.1007\/s10928-012-9293-x.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"8","key":"1123_CR19","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1128\/AAC.00050-08","volume":"52","author":"R Jansson","year":"2008","unstructured":"Jansson R, Malm M, Roth C, Ashton M. Enantioselective and nonlinear intestinal absorption of eflornithine in the rat. Antimicrob Agents Chemother. 2008;52(8):2842\u20138. https:\/\/doi.org\/10.1128\/AAC.00050-08.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"1123_CR20","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.pt.2014.08.002","volume":"30","author":"S Mogk","year":"2014","unstructured":"Mogk S, Meiwes A, Bosselmann CM, Wolburg H, Duszenko M. The lane to the brain: how African trypanosomes invade the CNS. Trends Parasitol. 2014;30(10):470\u20137. https:\/\/doi.org\/10.1016\/j.pt.2014.08.002.","journal-title":"Trends Parasitol"},{"issue":"7","key":"1123_CR21","doi-asserted-by":"publisher","first-page":"e0009583","DOI":"10.1371\/journal.pntd.0009583","volume":"15","author":"M Boberg","year":"2021","unstructured":"Boberg M, Cal M, Kaiser M, Jansson-Lofmark R, Maser P, Ashton M. Enantiospecific antitrypanosomal in vitro activity of eflornithine. PLoS Negl Trop Dis. 2021;15(7):e0009583. https:\/\/doi.org\/10.1371\/journal.pntd.0009583.","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"1123_CR22","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/0035-9203(93)90044-Q","volume":"87","author":"F Milord","year":"1993","unstructured":"Milord F, Loko L, Ethier L, Mpia B, Pepin J. Eflornithine concentrations in serum and cerebrospinal fluid of 63 patients treated for Trypanosoma brucei gambiense sleeping sickness. Trans R Soc Trop Med Hyg. 1993;87(4):473\u20137.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"2","key":"1123_CR23","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/clpt.1981.150","volume":"30","author":"KD Haegele","year":"1981","unstructured":"Haegele KD, Alken RG, Grove J, Schechter PJ, Koch-Weser J. Kinetics of alpha-difluoromethylornithine: an irreversible inhibitor of ornithine decarboxylase. Clin Pharmacol Ther. 1981;30(2):210\u20137.","journal-title":"Clin Pharmacol Ther"},{"key":"1123_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2019.09.015","author":"S Yang","year":"2019","unstructured":"Yang S, Chen Y, Feng M, Rodriguez L, Wu JQ, Wang MZ. Improving eflornithine oral bioavailability and brain uptake by modulating intercellular junctions with an E-cadherin peptide. J Pharm Sci. 2019. https:\/\/doi.org\/10.1016\/j.xphs.2019.09.015.","journal-title":"J Pharm Sci"},{"key":"1123_CR25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/b978-0-12-802395-2.00005-5","volume":"145","author":"V Leinonen","year":"2017","unstructured":"Leinonen V, Vanninen R, Rauramaa T. Cerebrospinal fluid circulation and hydrocephalus. Handb Clin Neurol. 2017;145:39\u201350. https:\/\/doi.org\/10.1016\/b978-0-12-802395-2.00005-5.","journal-title":"Handb Clin Neurol"},{"issue":"3","key":"1123_CR26","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3171\/jns.1983.59.3.0369","volume":"59","author":"JG McComb","year":"1983","unstructured":"McComb JG. Recent research into the nature of cerebrospinal fluid formation and absorption. J Neurosurg. 1983;59(3):369\u201383. https:\/\/doi.org\/10.3171\/jns.1983.59.3.0369.","journal-title":"J Neurosurg"},{"issue":"7","key":"1123_CR27","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1093\/jac\/dky128","volume":"73","author":"E Germovsek","year":"2018","unstructured":"Germovsek E, Lutsar I, Kipper K, Karlsson MO, Planche T, Chazallon C, et al. Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies. J Antimicrob Chemother. 2018;73(7):1908\u201316. https:\/\/doi.org\/10.1093\/jac\/dky128.","journal-title":"J Antimicrob Chemother"},{"key":"1123_CR28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1743-8454-5-10","volume":"5","author":"CE Johanson","year":"2008","unstructured":"Johanson CE, Duncan JA 3rd, Klinge PM, Brinker T, Stopa EG, Silverberg GD. Multiplicity of cerebrospinal fluid functions: New challenges in health and disease. Cerebrospinal Fluid Res. 2008;5:10. https:\/\/doi.org\/10.1186\/1743-8454-5-10.","journal-title":"Cerebrospinal Fluid Res"},{"issue":"7","key":"1123_CR29","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/bmc.1361","volume":"24","author":"R Jansson-Lofmark","year":"2010","unstructured":"Jansson-Lofmark R, Romsing S, Albers E, Ashton M. Determination of eflornithine enantiomers in plasma by precolumn derivatization with o-phthalaldehyde-N-acetyl-L-cysteine and liquid chromatography with UV detection. Biomed Chromatogr. 2010;24(7):768\u201373. https:\/\/doi.org\/10.1002\/bmc.1361.","journal-title":"Biomed Chromatogr"},{"key":"1123_CR30","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1007\/s00436-002-0766-5","volume":"90","author":"C Burri","year":"2003","unstructured":"Burri C, Brun R. Eflornithine for the treatment of human African trypanosomiasis. Parasitol Res. 2003;90:S49-52. https:\/\/doi.org\/10.1007\/s00436-002-0766-5.","journal-title":"Parasitol Res"},{"issue":"4","key":"1123_CR31","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1111\/j.1471-4159.2008.05706.x","volume":"107","author":"L Sanderson","year":"2008","unstructured":"Sanderson L, Dogruel M, Rodgers J, Bradley B, Thomas SA. The blood-brain barrier significantly limits eflornithine entry into Trypanosoma brucei brucei infected mouse brain. J Neurochem. 2008;107(4):1136\u201346. https:\/\/doi.org\/10.1111\/j.1471-4159.2008.05706.x.","journal-title":"J Neurochem"},{"issue":"10116","key":"1123_CR32","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/S0140-6736(17)32758-7","volume":"391","author":"V Mesu","year":"2018","unstructured":"Mesu V, Kalonji WM, Bardonneau C, Mordt OV, Blesson S, Simon F, et al. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial. Lancet. 2018;391(10116):144\u201354. https:\/\/doi.org\/10.1016\/S0140-6736(17)32758-7.","journal-title":"Lancet"},{"key":"1123_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30612-7","author":"AK Lindner","year":"2019","unstructured":"Lindner AK, Lejon V, Chappuis F, Seixas J, Kazumba L, Barrett MP, et al. New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice. Lancet Infect Dis. 2019. https:\/\/doi.org\/10.1016\/S1473-3099(19)30612-7.","journal-title":"Lancet Infect Dis"},{"key":"1123_CR34","doi-asserted-by":"publisher","unstructured":"Dickie EA, Giordani F, Gould MK, Maser P, Burri C, Mottram JC, et al. New Drugs for Human African Trypanosomiasis: A Twenty First Century Success Story. Trop Med Infect Dis. 2020;5(1). https:\/\/doi.org\/10.3390\/tropicalmed5010029.","DOI":"10.3390\/tropicalmed5010029"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01123-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-025-01123-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01123-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T17:59:07Z","timestamp":1762192747000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-025-01123-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["1123"],"URL":"https:\/\/doi.org\/10.1208\/s12248-025-01123-9","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Although authors M.B. and R.J.L. are currently employed by AstraZeneca R&D in Gothenburg, Sweden, AstraZeneca had no influence over the study. The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"139"}}